Fundamentals to Advanced Buprenorphine

This workshop, part of the Addiction Medicine Review Course 2019 focuses on the modern prescribing of buprenorphine for opioid use disorder. Core topics of pharmacology, side effect management, and regulations of buprenorphine treatment will be covered in a flipped-learning format using an on-demand webinar participants will view in advance. The on-site workshop will take a case-based approach. Advances including patient selection, regulatory compliance, low-threshold treatment and new formulations of buprenorphine will move your practice into the state of the art.


You must sign in or register on this site before purchasing using the link on the upper right corner of this page. Only after registering will you see the "Add to Cart" button. 

To purchase, click on the course (you do not need to select each lecture). After you have selected it, scroll to the bottom of the page and click "Add to Cart." 

You will be able to work through the lectures in any order by clicking on the lecture in the table below.  You may print out a CME certificate or transcript of your cumulative credits at any time.

Target Audience

  1. Physicians using buprenorphine for treatment of opioid use disorders in office-based practice.
  2. Other clinicians working working with patients prescribed buprenorphine in office-based treatment of opioid dependence

Learning Objectives

  1. Describe the epidemiology of opioid use disorder (OUD) and available pharmacological and non-pharmacological treatment modalities.
  2. Examine unique pharmacology and side effect profile of buprenorphine and discuss regulations and confidentiality issues related to buprenorphine treatment.
  3. Integrate evidence-based recommendations for Medical management of OUD with buprenorphine and its combination products, including recent and anticipated formulations of buprenorphine for OUD.
Course summary
Available credit: 
  • 2.00 AMA Category 1
  • 2.00 Attendance
Course opens: 
Course expires: 
  1. Introductions
  2. Barriers to Buprenorphine in Primary Care (Farah Zaidi, MD)
  3. Patient Selection for OBOT (Panel)
  4. Low Threshold Prescribing (Joseph Mega, MD)
  5. New Formulations (Matthew Torrington, MD, DFASAM)
  6. Fentanyl (David Kan, MD, DFASAM)
  7. Comfort Meds (Panel)
  8. Medical Board issues (David Kan, MD)
  9. Resource Review (David Kan, MD)
  10. Adjourn

David Kan, MD, DFASAM
Dr. David Kan is Chief Medical Officer of Bright Heart Health, the first of its kind addiction telehealth treatment program. Dr. Kan is also a psychiatrist in private practice in addiction, forensic and general psychiatry. Dr. Kan is the President of CSAM and the chair of the opioid committee. Dr. Kan has served CSAM as a member of the Board of Directors since 2011. Dr. Kan is active in political advocacy on behalf of all of our patients.

Farah Zaidi, MD 
Dr. Zaidi completed her psychiatry residency training from San Mateo County Psychiatry Residency Training Program and completed public psychiatry fellowship from ZSFGH/UCSF. She is a full time General and Adult psychiatrist and Psychiatry Residency Program's Core faculty at San Mateo County. She is also affiliated with Zuckerberg San Francisco General Hospital/UCSF in psychiatric emergency services. She is an active member of Suboxone committee at San Mateo Medical Center and is involved in advocacy for easy access of buprenorphine for patients with OUD. She is active in educating and encouraging primary care providers in getting X-Waivers for Buprenorphine prescriptions and have developed manual for Buprenorphine use by providers. She is also a primary author on hospital's methadone policy and writing policy for substance related impairment in psychiatry residents. She has given grand rounds talks on substance related impairment in healthcare providers. Some of her professional areas of interest include management of co-occurring, substance use and psychiatric disorders, psychodynamic issues in attachment with substances, residents and providers' education and substance use related impairment in health care providers. She is actively involved in CSAM for the past 5 years in different capacities and have been awarded MERF scholarship twice, 1st time as a resident trainee and 2nd time as a faculty. She plans to become Addiction Medicine Board Certified this year to continue and further her advocacy and support for patients struggling with addictions.

Matthew A. Torrington, MD
Dr. Torrington is a boarded by the American Academy of Family Medicine and the American Board of Addiction Medicine. He is a distinguished fellow of the American Society of Addiction Medicine, a member of the Committee on Treatment of Opioid Dependence of the California Society of Addiction Medicine and is a certified Medical Review Officer. Dr. Torrington maintains a private practice focusing on the longitudinal disease management of difficult addiction and pain cases. Dr Torrington’s clinical focus is on the treatment of stimulant dependence, alcohol dependence, opiate dependence, and pain. A participant in the development and implementation of significant research studies, he has served as Principle Investigator, co-investigator or study physician on numerous clinical trials. Dr Torrington has been involved in the clinical use, clinical research and education of physicians regarding buprenorphine for over 16 years.

Joseph Mega, MD, MPH 
Joseph Mega, MD, MPH currently serves as Medical Director for the Health Care for the Homeless program in Contra Costa County, California. Dr. Mega has been working to expand medication-assisted treatment (MAT) for opioid use disorder to homeless and vulnerable populations through novel delivery models, such as street outreach and low-barrier walk-in clinics. The Health Care for the Homeless program also manages the county's group-based MAT outpatient program, which currently serves over 600 patients. Dr. Mega is particularly interested in innovative efforts to expand addiction and harm-reduction services to vulnerable populations. In addition, Dr Mega has been working with the County Detention facilities to ensure patients have access to MAT while they are incarcerated and to naloxone upon release. He also works in the Emergency Department at the Contra Costa Regional Medical Center and has written the MAT protocols for the patients presenting to the Emergency. The hospital system was recently awarded the ED-BRIDGE grant to expand MAT services to all areas of the hospital and Dr Mega will be leading this expansion effort. Dr. Mega is a board-certified family medicine physician. He received his medical degree from Jefferson Medical College in Philadelphia and MPH at Johns Hopkins University in Baltimore. He completed his residency training at the Contra Costa Regional Medical Center Family Medicine program in Martinez, CA.


  1. David Kan, MD, DFASAM - Nothing to disclose
  2. Farah Zaidi, MD - Nothing to disclose
  3. Matthew A. Torrington, MD - Orexo: Speaker's Bureau, zubsolv speakers bureau 2015-19; Titan: Senior Master Trainer for Probuphine implant REMS
  4. Joseph Mega, MD, MPH - Nothing to disclose

The California Society of Addiction Medicine (CSAM) is accredited by the Institute for Medical Quality/California Medical Association to provide continuing medical education for physicians. CSAM takes responsibility for the content, quality and scientific integrity of this CME activity.

CSAM designates this live educational activity for a maximum of 2 AMA PRA Category 1 Credits™, Physicians should only claim credit commensurate with the extent of their participation in the activity. 

Continuing education credit is available for psychologists, therapists, substance use counselors, nurses and physician assistants.

Available Credit

  • 2.00 AMA Category 1
  • 2.00 Attendance


Please login or register to take this course.